New Jersey Better Educational Savings Trust acquired a new stake in NxStage Medical, Inc. (NASDAQ:NXTM) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 18,000 shares of the medical device company’s stock, valued at approximately $451,000.

Other hedge funds also recently made changes to their positions in the company. Norges Bank bought a new stake in shares of NxStage Medical during the fourth quarter valued at approximately $11,841,000. CWM LLC bought a new stake in shares of NxStage Medical during the second quarter valued at approximately $2,684,000. Bank of New York Mellon Corp increased its stake in shares of NxStage Medical by 0.5% in the first quarter. Bank of New York Mellon Corp now owns 639,866 shares of the medical device company’s stock valued at $17,168,000 after buying an additional 2,914 shares during the period. Russell Investments Group Ltd. increased its stake in shares of NxStage Medical by 67.9% in the first quarter. Russell Investments Group Ltd. now owns 28,847 shares of the medical device company’s stock valued at $773,000 after buying an additional 11,668 shares during the period. Finally, Adams Diversified Equity Fund Inc. increased its stake in shares of NxStage Medical by 2.8% in the first quarter. Adams Diversified Equity Fund Inc. now owns 41,000 shares of the medical device company’s stock valued at $1,100,000 after buying an additional 1,100 shares during the period. 91.11% of the stock is owned by institutional investors.

Shares of NxStage Medical, Inc. (NXTM) opened at 29.28 on Friday. The firm’s market cap is $1.93 billion. The company has a 50-day moving average of $24.75 and a 200 day moving average of $25.82. NxStage Medical, Inc. has a 52-week low of $20.45 and a 52-week high of $30.80.

NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.03) earnings per share. On average, equities analysts expect that NxStage Medical, Inc. will post ($0.04) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “New Jersey Better Educational Savings Trust Acquires Shares of 18,000 NxStage Medical, Inc. (NASDAQ:NXTM)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/new-jersey-better-educational-savings-trust-acquires-shares-of-18000-nxstage-medical-inc-nasdaqnxtm/1473889.html.

Several analysts have recently commented on NXTM shares. Northland Securities downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 4th. BidaskClub raised shares of NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, June 30th. William Blair downgraded shares of NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday. BTIG Research reaffirmed a “buy” rating and set a $27.00 price objective on shares of NxStage Medical in a research report on Wednesday, May 10th. Finally, Jefferies Group LLC downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $33.00 to $30.00 in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $30.29.

In related news, President Joseph E. Turk, Jr. sold 7,000 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $22.98, for a total value of $160,860.00. Following the sale, the president now directly owns 82,903 shares of the company’s stock, valued at $1,905,110.94. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Joseph E. Turk, Jr. sold 1,000 shares of the company’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $25.19, for a total value of $25,190.00. Following the completion of the sale, the president now directly owns 75,903 shares in the company, valued at $1,911,996.57. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,900 shares of company stock worth $1,404,073. 4.70% of the stock is owned by insiders.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.